1、Chair: Dr. Vivien Bramwell,NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP,Objectives - short-term,To undertake adjuvant studies to reduce recurrence and mortality due to metastases in early ASTS (Intergroup)GIST ACOSOG Z9001- will complete accrual
2、in 6 - 12 months- Canadian accrual approx. 10%STS INTERGROUP- Canadian participation in EORTC 62931 (closedDecember 2003)- several Intergroup proposals for RCT have failed, no agreement on appropriate control arm,limited efficacy current regimens in advanced STS,SARCOMA COMMITTEE/CANADIAN SARCOMA GR
3、OUP,Objectives - short-term,To perform empirical screening and/or rationally targeted studies of IND in chemotherapy-nave patients across spectrum ASTSfour phase II studies completed, published in last 10 yrschemo-nave patients, Intergroup collaboration in EORTC 62012 phase III trial of single agent
4、 DOX vs dose intense DOX/IFOS start Fall 2006,SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP,Objectives - short-term,To assess molecularly targeted therapies in histology- specific trials in patients who have failed conventional chemotherapy (Intergroup)ICAS Intergroup Coalition Against Sarcomas funded th
5、rough SWOG operating grant involves NCIC-CTG, ECOG, CALGBshared studies with RTOG, ACOSOG, COG S0033 imatinib in GIST (closed September 2001) accrued 746 pts in 9 mos (Canadian 7%) 4 IND studies open accruing through SWOG 3 on CTSU (1 awaiting Canadian activation, 2 declined) 3 future ICAS CTSU stud
6、ies Canadian interest 1 protocol, Canadian PI (Q. Chu) in development,SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP,Objectives - medium-term,To use research findings generated through the CSG TB/DB and/or IHRT program to plan future correlative science projects/clinical trialsCSG TB/DB (approximately 900
7、 frozen/fixed tumors and data) currently funded and maintained as part of larger TB/DB through IHRT program Mt. Sinai, Toronto IHRT program may morph into CanSarc (pending funding CIHR) IHRT/CanSarc projects, in future, may need national clinical trials involvement,SARCOMA COMMITTEE/CANADIAN SARCOMA
8、 GROUP,To build on local control, survival and functional outcome data from SR2 study, to plan future studies that will optimize local control and reduce morbidity in locoregional ASTStranslational, pilot studies ongoing through IHRT/CanSarc also may lead to future proposals for multicentre trials,SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP,Objectives - medium-term,
